Drugs / VVN461
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06906198 | Mar → May 2023 | — | VivaVision Biotech, Inc | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT06164743 | Jan → May 2024 | — | VivaVision Biotech, Inc | Completed | No outcome recorded |
| Phase 2 | NCT06679153 | Nov 2023 → Dec 2024 | anterior uveitis | VivaVision Biotech, Inc | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07136805 | Oct 2025 → Dec 2026 expected | non-infectious anterior uveitis | VivaVision Biotech, Inc | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VVN461 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07136805 ↗ |
| Route | Topical | “Topical ocular drug” NCT06164743 ↗ |